Uddin, a property developer, said: "I can't believe this has happened.
The Phase II trial is designed to evaluate the ability of patients to mount an immune response to their tumor and the potential for FavId
to enhance the response rate or prolong the time to progression following Rituxan treatment.
Despite the challenges faced by the sector, we predict that by 2010, there will be six new therapeutic cancer vaccine approvals, led by Favrille's FavId
for B-cell non-Hodgkin's lymphoma.
For instance, Favrille expects Favid
to be a blockbuster when approved for commercialisation.
For instance, Favrille is pinning its hopes on Favid
being a blockbuster when approved for commercialisation.
The Company intends to use the net proceeds from this offering to fund its efforts to obtain FDA approval for its lead drug candidate FavId
(R), to prepare for commercial launch of FavId
and for other general corporate purposes.
is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications.
AG-858, Aldesleukin , Alemtuzumab, AP23573, Apolizumab, Arsenic trioxide, Atra, Avastin, BAY 43-9006, Bevacizumab, BiovaxID , Bortezomib , CEP-701, Ceplene, Clofarabine, Cloretazine, CMC-544 , Decitabine, Enzastaurin , Epratuzumab, FavId
, FK228, Flavopiridol, Gemtuzumab, Genasense, Gvax, IDEC-114 , Imatinib, Marqibo, MyVax, Nelarabine , OSI-461, Pixantrone , PKC412, PTK787, Rituximab, SGN-30, SGN-40 , SU5416, Temsirolimus , Troxacitabine, Valspodar, VELCADE, Xcytrin, Zanolimumab, Zarnestra etc.
The Phase 3 trial is a randomized, double-blind, placebo controlled trial of FavId
following Rituxan(R) treatment in patients with follicular B-cell non-Hodgkin's lymphoma (NHL).
Commercializing a patient-specific immunotherapy product like FavId
requires a manufacturing process with an extensive paper batch record," said Tamara A.
Aldesleukin , Apolizumab, Arsenic trioxide, Bevacizumab, BiovaxID, Bortezomib, CMC-544 , Enzastaurin , Epratuzumab, FavId
, Flavopiridol, Genasense , IDEC-114 , Marqibo, MyVax, Nelarabine , Pixantrone, SGN-30, SGN-40, Temsirolimus, Zanolimumab.
Favrille's lead product candidate, FavId
, is currently in Phase III clinical trials and is being developed for use following treatment with Rituxan, the existing standard of care, to extend time to disease progression in patients with B-cell non-Hodgkin's lymphoma.